Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Veru gets a big Covid boost
But full data will be needed to confirm that sabizabulin is a real contender.
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Atea’s woes grow while other Covid readouts approach
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
Edesa finds a signal in severely ill Covid-19 patients
But other small biotechs are more advanced and still hope to play a role in the pandemic.
Early Covid-19 “win” boosts Veru
Veru’s victory with VERU-111 in Covid-19 is not as clear-cut as is being claimed.
